Over 1,500 DNA mutations have been implicated in cystic fibrosis, and as much as 5% of Caucasians have one or more of these markers.  Currently, CF is initially diagnosed in newborn screening from a blood test, but this method has significant false negatives and false positives.  Astra Biotech GmbH (Luckenwale, Germany) has developed a microarray panel that tests for 25 of the most common CF mutations, which holds promise for more accurate screening.  MORE